Please login to the form below

Debiopharm

This page shows the latest Debiopharm news and features for those working in and with pharma, biotech and healthcare.

Merck and Roche team up for hepatitis C studies

Meanwhile, a range of other new HCV drugs are coming through the pharma industry's pipelines, including Novartis and Debiopharm's DEB025, Boehringer Ingelheim's BI 201335, Bristol-Myers Squibb 's

Latest news

More Eloxatin settlements for sanofi-aventis

Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.
Sanofi-aventis settles Eloxatin lawsuits

medicine. S-A, who hold patent rights for the drug along with Swiss-based Debiopharm, did not give any other details regarding the recent settlements, including financial.
Novartis gain rights to hepatitis C drug

The Swiss drugmakers will make an undisclosed upfront payment to Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, with Novartis receiving exclusive worldwide development and marketing rights (excluding Japan).
HCV hope on the horizon

The ciclosporin analogue DEBIO 025 (Debiopharm) is a first-in-class cyclophilin inhibitor that has been generally well tolerated in clinical trials to date and may have potential as an addition
Pandemic preparedness

Micombi (Nippon Boehringer Ingelheim, Astellas Pharma). Hypertension. Japan. Triptorelin. Salvacyl (Debiopharm).